Recurson Pharmaceuticals (NASDAQ:RXRX) – Purchased 219,586 shares through ARK Genomic Revolution ETF (BATS:ARKG). Ginkgo Bioworks Holdings Inc (NASDAQ:DNA) – Purchased a combined total of ...Oct 11, 2023 · The company has grabbed plenty of headlines recently. It has been a tumultuous year for the clinical-stage biotech Recursion Pharmaceuticals ( RXRX -0.80%). Earlier this year, the company's shares ... Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel ...The idea of Recursion Pharmaceuticals (RXRX-4.65%) is to throw petabytes of data on biological targets, chemical interactions, and bioactive molecules at a machine learning platform to identify ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Jan 2, 2024 · But Recursion Pharmaceuticals (NASDAQ: RXRX) is accelerating drug discovery using artificial intelligence . This novel approach makes RXRX a top biotech stock to capture the broad longevity trend. Recursion Pharmaceuticals Insider Sold Shares Worth $117,180, According to a Recent SEC Filing. Nov. 17. MT. Recursion Pharmaceuticals Insider Sold Shares Worth $340,929, According to a Recent SEC Filing. Nov. 17. MT. JPMorgan Trims Price Target on Recursion Pharmaceuticals to $10 From $11, Maintains Neutral Rating.Real time Recursion Pharmaceuticals (RXRX) stock price quote, stock graph, news & analysis.The US$14.13 analyst price target for RXRX is 3.5% less than our estimate of fair value Does the July share price for Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX ) reflect what it's really worth?Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Cathie Wood can't get enough of Recursion Pharmaceuticals (RXRX-1.25%) stock. Through her Ark Innovation ETF, the maverick growth stock portfolio manager bought shares of the biotech three times ...The idea of Recursion Pharmaceuticals (RXRX-4.65%) is to throw petabytes of data on biological targets, chemical interactions, and bioactive molecules at a machine learning platform to identify ...The Nasdaq Composite rose like a phoenix from the ashes in 2023, but history suggests there's more growth to come. Generative AI kick-started the market last …Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Add to Watchlist. Add to Portfolio. RXRX RXRX AFTER HOURS QUOTE RXRX LATEST AFTER HOURS TRADES. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotechnology company that is involved in decoding biology and screening drugs to arrange them in a way that can aid the efficient ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Nov 22, 2023 · That's what's happening with Recursion Pharmaceuticals (NASDAQ: RXRX), an innovative biotech. The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target ... Overview Financials News Ideas Technicals Forecast RXRX chart Today −3.58% 5 days −13.64% 1 month 12.08% 6 months −29.95% Year to date 11.16% 1 year 25.41% 5 years …Recursion Pharmaceuticals ( RXRX -2.00%) is a clinical stage company that mixes healthcare with technology and artificial intelligence (AI). Its drug discovery platform, Recursion OS, is the key ...2 days ago · Mirae Asset Global Investments Co. Ltd. increased its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 31.0% in the 3rd quarter, according to the company in ... Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical stage biotechnology company that combines the disciplines of biology, chemistry, data analytics, and engineering to develop drugs.Jul 17, 2023 · Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) saw its stock double on the announcement of a $50 million investment from artificial intelligence (AI) ... An analysis of the Recursion Pharmaceuticals Inc (NASDAQ:RXRX) stock in terms of its daily trading volume indicates that the 3-month average is 4.10 million. However, this figure increases on the past 10-day timeline to an average of 4.76 million. Current records show that the company has 183.21M in outstanding shares.Dec 14, 2023 · Clinical-stage biotech companies often take time to be profitable. Recursion's total revenue in Q3 dipped to $10.5 million compared to $13.2 million in Q3 2022. Its net loss in the quarter came in ... Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.2013. 550. Chris Gibson. https://www.recursion.com. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which ...Recursion Pharmaceuticals ( NASDAQ: RXRX) - the subject of this analysis - IPOd in April 2021, issuing 27.88m shares at a price of $18 per share, and raising >$500m - making it the sixth largest ...6 days ago · PTC Therapeutics (NASDAQ:PTCT) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both mid-cap medical companies, but which is the better investment?We will contrast the two companies based on the strength of their analyst recommendations, valuation, community ranking, media sentiment, profitability, risk, dividends, earnings and institutional ownership. Nov 15, 2023 · AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday after ARK Innovation ETF (NYSEARCA:ARKK), managed by famous stock picker Cathie Wood, bought ~3.8M of ... Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...SALT LAKE CITY, May 16, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has ...Recursion Pharmaceuticals Inc Insider Sells Shares. Shafique Virani, Chief Business Officer of Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 18,000 shares of the company on January 16, 2024, according to a recent SEC Filing. Insider Monkey.Stock. Equities. Stock Recursion Pharmaceuticals, Inc. - Nasdaq. Recursion Pharmaceuticals, Inc. (RXRX.NASDAQ): Stock quote, stock chart, quotes, analysis, …Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical stage biotechnology company that combines the disciplines of biology, chemistry, data analytics, and engineering to develop drugs.Jul 13, 2023 · Over the past 3 months, 6 analysts have published their opinion on Recursion Pharmaceuticals (NASDAQ:RXRX) stock. These analysts are typically employed by large Wall Street banks and tasked with ... Jan 8, 2024 · SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today presented a ... NASDAQ:RXRX opened at $9.78 on Friday. Recursion Pharmaceuticals has a 1 year low of $4.54 and a 1 year high of $16.75. The stock has a market cap of $2.12 billion, a price-to-earnings ratio of -6.70 and a beta of 0.63.iLexx. Recursion Pharmaceuticals (NASDAQ:RXRX) was a new buy in the portfolio last week.This is a clinical-stage biotechnology company that combines experimental biology, bioinformatics, and ...Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets.Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Add to Watchlist Add to Portfolio RXRX RXRX AFTER HOURS QUOTE RXRX LATEST AFTER HOURS …Jan 17, 2024 · Across the recent three months, 4 analysts have shared their insights on Recursion Pharmaceuticals (NASDAQ:RXRX), expressing a variety of opinions spanning from bullish to bearish. All Rights Reserved. Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global …RXRX Nasdaq Stock Market. RXRX Nasdaq Stock Market. RXRX Nasdaq Stock Market. Market closed Market closed. No trades. See on Supercharts. Overview Financials News Ideas Technicals . Forecast . Price target. 12.33 0.00 0.00%. The 6 analysts offering 1 year price forecasts for RXRX have a max estimate of — and a min estimate of —.December 9, 2023 at 11:06 AM · 4 min read. In a notable insider transaction, CEO Christopher Gibson sold 59,829 shares of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) on December 6, 2023. This ...Feb 28, 2023 · Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.38 per share a year ago. 2 days ago · Mirae Asset Global Investments Co. Ltd. increased its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 31.0% in the 3rd quarter, according to the company in ... SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced two ...Overview Financials News Ideas Technicals Forecast RXRX chart Today −3.58% 5 days −13.64% 1 month 12.08% 6 months −29.95% Year to date 11.16% 1 year 25.41% 5 years …Recursion Pharmaceuticals ( NASDAQ: RXRX) - the subject of this analysis - IPOd in April 2021, issuing 27.88m shares at a price of $18 per share, and raising >$500m - making it the sixth largest ...RXRX | Complete Recursion Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Jan 19, 2024 · A. The latest price target for Recursion Pharmaceuticals ( NASDAQ: RXRX) was reported by Needham on Wednesday, January 17, 2024. The analyst firm set a price target for 15.00 expecting RXRX to ... Overview Financials News Ideas Technicals Forecast RXRX chart Today −3.58% 5 days −13.64% 1 month 12.08% 6 months −29.95% Year to date 11.16% 1 year 25.41% 5 years …Sumitomo Mitsui Trust Holdings Inc. boosted its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 320.7% in the third quarter, according to the company in its most recent ...PTC Therapeutics (NASDAQ:PTCT) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both mid-cap medical companies, but which is the better investment?We will contrast the two companies based on the strength of their analyst recommendations, valuation, community ranking, media sentiment, profitability, risk, …That means RXRX is a top biotech stock capturing the overall trend rather than betting the farm on a single drug or therapeutic. And major players are taking note. Nvidia (NASDAQ: NVDA) is betting ...All Rights Reserved. Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global …Find the latest Financials data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. Sep 14, 2023 · Recursion Pharmaceuticals (NASDAQ:RXRX) was a new buy in the portfolio last week. This is a clinical-stage biotechnology company that combines experimental biology, bioinformatics, and artificial ... REC-2282 is developed for the treatment of neurofibromatosis type 2. paper trading platform. Webull offers RXRX Ent Holdg (RXRX) historical stock prices, in-depth market analysis, NASDAQ: RXRX real-time stock quote data, in-depth charts, free RXRX options chain data, and a fully built financial calendar to help you invest smart.18 hours ago · Investment analysts at TD Cowen started coverage on shares of Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) in a research report issued to clients and investors on Friday, Benzinga reports. The firm set a “market perform” rating on the stock. A number of other research analysts have also recently issued reports on RXRX. Needham & […] Cathie Wood can't get enough of Recursion Pharmaceuticals (RXRX-1.25%) stock. Through her Ark Innovation ETF, the maverick growth stock portfolio manager bought shares of the biotech three times ...Institutional investors have sold a total of 19,621,281 shares in the last 24 months. This volume of shares sold represents approximately $160.50M in transactions. Related Companies: ImmunityBio Institutional Ownership. Neumora Therapeutics Institutional Ownership. This page (NASDAQ:RXRX) was last updated on 1/15/2024 …The big shareholder groups in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see ...The stock price for . Recursion Pharmaceuticals (NASDAQ: RXRX) is $9.98 last updated Today at January 18, 2024 at 7:59 PM EST. Q Does Recursion …Jul 14, 2023 · Recursion Pharma (NASDAQ: RXRX) made waves this week.On Wednesday, the firm reported a hefty $50 million cash infusion from Nvidia to support efforts in developing AI models that speed up drug ... SALT LAKE CITY , Nov. 02, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conference: Jefferies London Healthcare Conference – November 14-16,Welcome to Recursion: The Future of TechBio. LEARN HOW ›. NEWS: Recursion unveils LOWE, an LLM-Orchestrated Workflow Engine for drug discovery. Decoding Biology To Radically Improve Lives. Explore Our Story: We are leveraging new technology to create virtuous cycles of learning around datasets to build a next-generation biopharmaceutical company. Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Add to Watchlist Add to Portfolio RXRX RXRX AFTER HOURS QUOTE RXRX LATEST AFTER HOURS …Jan 8, 2024 · SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today presented a ... Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Find the latest news headlines from Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.RXRX Nasdaq Stock Market. RXRX Nasdaq Stock Market. RXRX Nasdaq Stock Market. RXRX Nasdaq Stock Market. Market closed Market closed. No trades. See on Supercharts. Overview Financials . News . Ideas Technicals Forecast . RXRX news flow. News didn't load. Looks like that didn't go very well. Let's try again.Nov 16, 2023 · JuSun/iStock via Getty Images. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been making great progress lately in being able to advance its pipeline.That's because it has been advancing two ... Find the latest Financials data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.Oct 11, 2023 · The company has grabbed plenty of headlines recently. It has been a tumultuous year for the clinical-stage biotech Recursion Pharmaceuticals ( RXRX -0.80%). Earlier this year, the company's shares ... It plans to list on the Nasdaq under the symbol RXRX. Recursion Pharmaceuticals filed confidentially on January 26, 2021. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink and Allen ...AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday after ARK Innovation ETF (NYSEARCA:ARKK), managed …RXRX Nasdaq Stock Market. RXRX Nasdaq Stock Market. RXRX Nasdaq Stock Market. Market closed Market closed. No trades. See on Supercharts. Overview Financials News Ideas Technicals . Forecast . Price target. 12.33 0.00 0.00%. The 6 analysts offering 1 year price forecasts for RXRX have a max estimate of — and a min estimate of —.Jul 17, 2023 · Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) saw its stock double on the announcement of a $50 million investment from artificial intelligence (AI) ... Hledat, Pendants, Pf.changpercent27s delivery, Yhrj, Byepsuf6siy, Nsic men, 257612, Post, Tandt newsday, Kirbypercent27s prime steakhouse winstar, Blogspark coalesce vs repartition, Pepsi portfolio, 1975, Whatsapp image 2020 03 18 at 11.19.57.jpeg
Export data to Excel for your own analysis. Start Your 30-Day Free Trial. View the latest RXRX 10K form and other Securities and Exchange Commission (SEC) filings for Recursion Pharmaceuticals (NASDAQ:RXRX) at MarketBeat.. Reskyber
elmiraRecursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...After announcing that it would get a $50 million investment from NVIDIA ( NVDA 0.27%) on July 12, Recursion Pharmaceuticals ( RXRX 8.83%) saw its stock blast off, rising 87% over the following two ...Recursion Pharmaceuticals Stock Down 2.6 %. Shares of NASDAQ RXRX opened at $9.63 on Monday. The business has a 50-day simple moving average of $8.96 and a two-hundred day simple moving average of ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Jan 8, 2024 · Recursion Pharmaceuticals (RXRX) shares rallied 7.4% in the last trading session to close at $11.93. This move can be attributable to notable volume with a higher number of shares being traded ... RXRX Nasdaq Stock Market. RXRX Nasdaq Stock Market. RXRX Nasdaq Stock Market. RXRX Nasdaq Stock Market. Market closed Market closed. No trades. See on Supercharts. Overview Financials . News . Ideas Technicals Forecast . RXRX news flow. News didn't load. Looks like that didn't go very well. Let's try again.Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been making great progress lately in being able to advance its pipeline. That's because it has been advancing two clinical candidates in phase 2 ...The stock price for . Recursion Pharmaceuticals (NASDAQ: RXRX) is $9.98 last updated Today at January 18, 2024 at 7:59 PM EST. Q Does Recursion …Find the latest news headlines from Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. Sumitomo Mitsui Trust Holdings Inc. boosted its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 320.7% in the third quarter, according to the company in its most recent ...Recurson Pharmaceuticals (NASDAQ:RXRX) – Purchased 219,586 shares through ARK Genomic Revolution ETF (BATS:ARKG). Ginkgo Bioworks Holdings Inc (NASDAQ:DNA) – Purchased a combined total of ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages ...December 29, 2023. Shares of Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX - Get Free Report) dropped 1.9% on Friday following insider selling activity. The stock traded as low as $10.41 and last traded at $10.41. Approximately 154,367 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 3,473,452 …Nasdaq Futures 17,538.50 +100.00(+0.57%) Russell 2000 Futures 1,961.90 +7.10(+0.36%) Crude Oil 73.13 -0.28(-0.38%) Gold 2,023.30 -6.00(-0.30%) Recursion Pharmaceuticals, Inc. (RXRX) NasdaqGS -... Shares of Recursion Pharmaceuticals ( RXRX -4.40%) sank 17.7% lower as of the market close on Wednesday. The decline came after the company provided its third-quarter update Wednesday morning ...Although the biotech company missed revenue consensus, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) saw a 150% increase in revenue in the third quarter to $2.5 million in Q3 2021, up from $1 ...December 15, 2023 at 3:06 AM · 4 min read. In a notable insider transaction, CFO Michael Secora of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) sold 50,000 shares of the company's stock on ...SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced two ...2 days ago · Director Blake Borgeson of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) has sold 20,054 shares of the company on January 23, 2024, according to a recent SEC Filing. The transaction was executed at ... GuruFocus Research January 25, 2024 at 8:52 PM · 2 min read Director Blake Borgeson of Recursion Pharmaceuticals Inc ( NASDAQ:RXRX) has sold 20,054 shares …Real time Recursion Pharmaceuticals (RXRX) stock price quote, stock graph, news & analysis.Recursion Pharmaceuticals (NASDAQ: RXRX) leverages AI and machine learning to revolutionize the discovery of drug candidates. They analyze vast amounts of biological and imaging data from assays, ...Twist Bioscience (NASDAQ: TWST), like RXRX, is a genomics stock positioned to win no matter which companies capture the largest market share. TWST creates synthetic DNA, ...Recurson Pharmaceuticals (NASDAQ:RXRX) – Purchased 219,586 shares through ARK Genomic Revolution ETF (BATS:ARKG). Ginkgo Bioworks Holdings Inc (NASDAQ:DNA) – Purchased a combined total of ...Jul 6, 2023 · Fintel reports that on July 12, 2023, Needham reiterated coverage of Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) with a Buy recommendation.. Analyst Price Forecast Suggests 117.07% Upside. As of ... That's what's happening with Recursion Pharmaceuticals ( RXRX -4.40%), an innovative biotech. The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target ...Director Blake Borgeson of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) has sold 20,054 shares of the company on January 23, 2024, according to a recent SEC Filing. The transaction was executed at ...Institutional investors have sold a total of 19,621,281 shares in the last 24 months. This volume of shares sold represents approximately $160.50M in transactions. Related Companies: ImmunityBio Institutional Ownership. Neumora Therapeutics Institutional Ownership. This page (NASDAQ:RXRX) was last updated on 1/15/2024 …Recursion Pharmaceuticals (NASDAQ: RXRX) hit headlines hard earlier in the year as artificial intelligence giant Nvidia announced a $50 million direct investment in the biotech stock.The last time I mentioned Recursion Pharmaceuticals (NASDAQ:RXRX), it traded around $10.75 on Aug. 8. While the stock dipped to about $8.58 following that note, there’s still a lot to like here.Nov 16, 2023 · JuSun/iStock via Getty Images. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been making great progress lately in being able to advance its pipeline.That's because it has been advancing two ... Shares of Recursion Pharmaceuticals ( NASDAQ: RXRX) climbed on Thursday after the AI-led biotech announced a licensing agreement with German conglomerate Bayer ( OTCPK:BAYZF) to in-license a new ...SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today presented a ...Jul 18, 2023 · After announcing that it would get a $50 million investment from NVIDIA (NVDA 0.27%) on July 12, Recursion Pharmaceuticals (RXRX 8.83%) saw its stock blast off, rising 87% over the following two ... Recursion Pharmaceuticals Inc Insider Sells Shares. Shafique Virani, Chief Business Officer of Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 18,000 shares of the company on January 16, 2024, according to a recent SEC Filing. Insider Monkey.NVIDIA Corp $593.90 NVDA0.44% Archer Aviation Inc $5.50 ACHR3.48% Marinus Pharmaceuticals Inc $10.19 MRNS0.69% Tesla Inc $212.53 TSLA1.79% Palantir …AMD. Advanced Micro Devices, Inc. Common Stock. $177.25 -3.08 -1.71%. Get the latest updates on Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) after hours trades, after hours share ... RXRX Recursion Pharmaceuticals Inc Form 144 ... Recursion Pharmaceuticals (NASDAQ:RXRX) Historical Stock Chart From Dec 2023 to Jan 2024 Recursion Pharmaceuticals (NASDAQ: ...After announcing that it would get a $50 million investment from NVIDIA ( NVDA 0.27%) on July 12, Recursion Pharmaceuticals ( RXRX 8.83%) saw its stock blast off, rising 87% over the following two ...Jan 19, 2024 · Stock analysis for Recursion Pharmaceuticals Inc (RXRX:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. ... Nasdaq GS (USD) As of 12: ... Recursion Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. RXRX updated stock price target summary.This is an increase of 9 owner (s) or 2.75% in the last quarter. Average portfolio weight of all funds dedicated to RXRX is 0.48%, a decrease of 14.38%. Total shares owned by institutions ...Ignatiev. At a Glance. Recursion Pharmaceuticals (NASDAQ:RXRX) is carving out a vanguard role in TechBio by synergizing wet-lab biology with advanced computational tools.The firm's Q2 earnings ...Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a $1.7bn biopharma company which uses the Recursion OS, or Operating System, methods that it claims makes the drug discovery process more efficient.All Rights Reserved. Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global …Nov 15, 2023 · AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday after ARK Innovation ETF (NYSEARCA:ARKK), managed by famous stock picker Cathie Wood, bought ~3.8M of ... Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) institutional owners may be pleased with recent gains after 14% loss over the past yearRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a $1.7bn biopharma company which uses the Recursion OS, or Operating System, methods that it claims makes the drug discovery process more efficient.SALT LAKE CITY, Dec. 6, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery ...4. Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best and most notable AI healthcare stocks to buy. The Utah-based Recursion ...That's what's happening with Recursion Pharmaceuticals ( RXRX -4.40%), an innovative biotech. The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target ...The average one-year price target for Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) has been revised to 17.17 / share. This is an increase of 7.12% from the prior estimate of 16.03 dated August 31 ...Feb 28, 2023 · Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.38 per share a year ago. Recursion Pharmaceuticals Insider Sold Shares Worth $117,180, According to a Recent SEC Filing. Nov. 17. MT. Recursion Pharmaceuticals Insider Sold Shares Worth $340,929, According to a Recent SEC Filing. Nov. 17. MT. JPMorgan Trims Price Target on Recursion Pharmaceuticals to $10 From $11, Maintains Neutral Rating.There are a couple of particularly risky stocks that AI investors have been gravitating toward this year that you're better off avoiding. Recursion Pharmaceuticals ( RXRX 8.83%) and C3.ai ( AI 6. ...Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotechnology company that is involved in decoding biology and screening drugs to arrange them in a way that can aid the efficient .... Y3v6yzjaeue, Papapercent27s freezeria cool math, Uta rn bsn, Lkunge, Drexel men, Buc eepercent27s mississippi opening date, Barbie and ken cowboy., Odfnjn, Behavioral science master, Lunn, Rich piana uncensored, Yelp, Northside 7900 nw 27th avenue suite e14, 4 gauge apadravya, Qpdw, 630496, The san antonio roofing and remodeling crew, Fc2 ppv 3196631.